Overall, SR - Tiget represents a multi-disciplinary research environment, which provides a unique blend of scientific expertise in the development of innovative
gene and cell therapy strategies, access to relevant preclinical models to evaluate their efficacy and safety, as well as competence in conducting early phase clinical trials.
Not exact matches
Muscle biologists Qi Long Lu
and Terence Partridge at the Medical Research Council Clinical Sciences Centre in London, U.K.,
and their colleagues decided to combined the antisense
strategy with a chemical often used in
gene therapy because it is known to improve delivery of DNA into
cells.
Although the
gene /
cell therapy strategy was highly successful in laboratory mice, the authors stressed that additional research
and testing are needed before the
therapy could be tested in humans.
Therapeutic
strategies aiming at restoring the function of the implicated
genes (
gene and cell therapies) are very encouraging but not applicable in a near future to the variety of MDs.
The third Objective (IRF3) brings together promising scientists
and clinicians from the University of Pennsylvania
and the Rockefeller University to combine
gene therapy strategies, independently tested in humans, with the goal of engineering, growing,
and administering killer
cells that are uniquely empowered to find
and kill HIV - infected
cells.
This work, published in «Blood», was carried out by the CNIO Telomeres
and Telomerase Group The treatment is based on the transport of the telomerase
gene to the bone marrow
cells using
gene therapy, a completely new
strategy in the treatment of aplastic anaemia